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Background: Severe malaria remains a major cause of death and morbidity amongst adults in the Asiatic tropics.
Methods: A retrospective analysis of the clinical and laboratory data of 988 adult patients, hospitalized with
Plasmodium falciparum malaria and prospectively recruited to malaria studies in western Thailand between 1986
and 2002, was performed to assess the factors associated with a fatal outcome. Different severity scores and
classifications for defining severe malaria were compared and, using multiple logistic regression, simple models for
predicting mortality developed.
Results: The proportion of patients fulfilling the WHO 2000 definition of severe malaria was 78.1%, and their mortality
was 10%. Mortality in patients given parenteral artesunate or artemether (16/317, 5%) was lower than in those given
parenteral quinine (59/442, 13%) (P < 0.001). Models using parameter sets based on WHO 1990, 2000 and Adapted AQ
criteria plus blood smear parasite-stage assessment gave the best mortality prediction. A malaria prognostic index (MPI),
derived from the dataset using five clinical or laboratory variables gave similar prognostic accuracy.
Conclusions: The mortality of severe malaria in adults has fallen and the switch from quinine to artesunate has probably
been an important contributor. Prognostic indices based on WHO 2000 definitions, and other simpler indices based on
fewer variables, provide clinically useful predictions of outcome in Asian adults with severe malaria.
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Plasmodium falciparum malaria still kills ~0.7 million
people each year. The majority of those who die are chil-
dren in sub-Saharan Africa, but ~43,000 patients still die
each year in the Asia-Pacific [1]. Admission clinical fea-
tures that predict death have been defined in African
children [2-6]. For Asian adults the relationships between
mortality and a wide range of individual variables have
been tested, including parasitaemia and parasite-stage
distribution and intraleucocytic malaria pigment on
blood smears, renal failure, hypoglycaemia, cerebral
malaria, acidosis and older age [7-14] (Additional file 1,
Tables 1 and 2). However, there have been few assessments* Correspondence: paul@tropmedres.ac
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reproduction in any medium, provided the orof which combinations of prognostic factors are the best
predictors of mortality. Although a single definition may
not be appropriate everywhere, it is important to at-
tempt to define severe malaria to aid clinicians in recog-
nizing those at risk of death and in need of parenteral
therapy. This will inform decisions on whether transfer
to a higher level of care, if available, is appropriate, facilitate
comparison between datasets, longitudinal epidemiological
surveillance, and robust case definitions in evaluation of
interventions [11,15].
Several definitions, classifications and severity scores
have been proposed. The World Health Organization
(WHO) has produced three guidelines which include
definitions of severe malaria (Additional file 1, Tables 1
and 2) [16-18]. A slightly stricter definition of severe mal-
aria (‘AQ’) was developed for a clinical trial in Vietnam
[19] and adapted (with the addition of plasma lactate and
serum bicarbonate measurements) for a trial in Thailandl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinical variables included in the ten sets, used in the logistic regression analyses
Variable Bed
side
Bedside and
simple lab
WHO
1990
WHO
2000
Adapted
AQ
Adapted AQ
plus late stages
BCAM RCAM MSA MPI
Seizures before admission X X X X - - - - - -
Clinical anaemia X X - - - - - - - -
Clinical jaundice X X X X - - - - - -
Bleeding - - X X - - - - - -
Blackwater fever - - X X - - - - - -
Temperature X X X - - - - - - -
Pulse X X - - - - - - - -
Respiratory rate X X - X - - - X - -
Respiratory distress, requiring
mechanical ventilation
- - - - - - - - X -
Liver palpable X X - - - - - - - -
GCS Total X X X X X X X X X X
Pulmonary oedema - - X X - - - - - -
X = included, - = not included.
BCAM score uses serum bicarbonate as a marker of acidosis with cut-off values of ≥24 mmol/L (score = 0) for normal, ≥15- < 24 mmol/L (score = 1) for deranged,
and <15 mmol/L (score = 2) for very deranged along with thresholds for coma of GCS ≤14 and GCS ≤10 [23]. The acidosis and coma scores were summed to give
the BCAM score, ranging from 0–4.
RCAM score uses respiratory rate as a surrogate marker for acidosis with cut offs of <20 breaths/min (score = 0) for normal, 20–39 breaths/min (score = 1) for
deranged, and ≥40 breaths/min (score = 2) for very deranged.
The MSA score was defined as sum of 1 (severe anaemia [haemoglobin, <5 g/dL]) + 2 (acute renal failure [serum creatinine, >3 mg/dL or 250 μmol/L]) + 3
(respiratory distress, requiring mechanical ventilation) + 4 (cerebral malaria [GCS <11]), in which each variable was scored as 0 or 1, depending on its absence or
presence, respectively [22].
Table 2 Laboratory variables included in the ten sets, used in the logistic regression analyses
Blood test variable Bed
side
Bedside and
simple lab
WHO
1990
WHO
2000
Adapted
AQ
Adapted AQ
plus late stages
BCAM RCAM MSA MPI
Admission parasitaemia - X X X X X - - - X
Pigmented stages - X - - - X - - - X
Modal Stage - X - - - - - - - -
Haematocrit - X X X X X - - - -
Haemoglobin - - - - - - - - X -
White cell count - - - - - - - - - -
Potassium S - - - - - - - - - -
Creatinine S - - X X X X - - X -
Urea S - - - - - - - - - -
Urea:creatinine ratio S - - - - - - - - - -
Total bilirubinS - - X - X X - - - X
Direct bilirubin S - - - - - - - - - -
Alkaline phosphatase S - - - - - - - - - -
AST S - - - - - - - - - -
ALT S - - - - - - - - - -
Albumin S - - - - - - - - - -
Bicarbonate S - - X X X X X - - -
Glucose P - - X X X X - - - -
Lactate P - - - X X X - - - X
X = included, - = not included. S = serum, P = plasma.
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which enrolled 1461 Asian patients [21]. The malaria se-
verity assessment score (MSA), based on haemoglobin,
serum creatinine, requirement for mechanical ventilation
and Glasgow coma score (GCS) was developed in central
India [22].
Recently, in order to simplify and, therefore, broaden
usage, the coma acidosis malaria (CAM) score was de-
veloped [23], based on data from Asian adults with se-
vere malaria [21]. A score of <2/5, when tested with data
from different studies in Vietnamese and Bangladeshi
adults, had a positive predictive value (PPV) for survival
of 94-95%, suggesting that these patients could be cared
for without admission to an intensive care unit (ICU).
The clinical and laboratory features of adults with
falciparum malaria recruited prospectively to hospital-
based studies on the western border of Thailand between
1986–2002, conducted by the Mahidol University-Oxford
Tropical Medicine Research Unit and colleagues, were
analysed. The specificity and sensitivity of the different
severe malaria definitions and scoring systems were ex-
amined and simple models to identify adults at risk of
death built.
Methods
Study sites, years and studies
Data from 988 adult (≥15 years) patients with asexual
forms of P. falciparum present on peripheral blood slides,
admitted to hospital with malaria and then recruited to
clinical research studies on the western border of
Thailand between 1986 and 2002 were analysed. Patients
were recruited at hospitals in Kanchanaburi (1986–1993;
n = 571), Sangklaburi (1994–1995; n = 74), and Mae Sot
(1995–2002; n = 343) and described in a series of pa-
pers [24]. All patients gave informed consent to partici-
pation and all studies were approved by the Ethics
Committee of the Faculty of Tropical Medicine, Mahidol
University and/or the Ethical and Scientific Review Sub-
committee of the Ministry of Public Health, Government
of Thailand.
Clinical and laboratory assessment
As patients were recruited to a variety of studies, clinical
and laboratory evaluations varied. All patients had a full
history and examination performed and haematocrit and
parasitaemia determined. Thick and thin blood films
were stained immediately with Field’s stain and parasites
counted and staged [7,8]. Admission blood samples for
full blood count, serum sodium, potassium, creatinine,
urea, total bilirubin, direct bilirubin, alkaline phosphat-
ase, alanine transaminase (ALT), aspartate transaminase
(AST), plasma lactate, glucose and, except in 1994, for
plasma bicarbonate. Lumbar punctures were performed
for the majority of patients with reduced GCS andcerebrospinal fluid cell, protein and glucose concentrations
determined and Gram stains examined.
Management
The anti-malarial treatment regimens used in clinical
studies in western Thailand changed over the 18 years as
new anti-malarials were introduced and were:
1. Non-artemisinin-based parenteral treatment:
Intravenous quinine dihydrochloride with or without
a 20 mg salt/kg or 7 mg/kg loading dose followed by
10 mg/kg every 8 h followed by oral quinine salt
10 mg/kg every 8 h, combined, when the patient
was able to take oral medication, with oral quinine
alone or with oral tetracycline, doxycycline,
mefloquine (alone or combined with sulphadoxine-
pyrimethamine (SP)) or single dose primaquine to
give a total treatment course of 7 days.
2. Non-artemisinin-based oral treatment:
Oral quinine sulphate 10 mg salt/kg every 8 h alone
or with oral tetracycline, doxycycline, mefloquine
(alone or combined with SP), single dose primaquine
or proguanil to give a total treatment course of 7 days.
Or oral mefloquine (alone or combined with SP) at
15 mg base/kg on the first day with or without 10
mg/kg on the next day
Or oral halofantrine (8 mg/kg at 0, 6, 12 h) with
tetracycline plus or minus oral quinine
3. Artemisinin-based parenteral treatment:
Intravenous artesunate (Guilin Pharmaceutical Factory
No. 2, Guangxi, People’s Republic of China); 2.4 mg/kg
stat, 1.2 mg/kg at 12 h followed by 1.2 mg/kg every
24 h) or intramuscular artemether (3.2 mg/kg stat
followed by 1.6 mg/kg every 24 h) for 7 days alone
or with oral doxycycline, tetracycline or mefloquine
(alone or combined with SP) with or without
primaquine. Sixty-nine patients were treated with iv
artesunate combined with iv quinine followed by the
above oral regime [25].
4. Artemisinin-based oral treatment:
Oral artesunate or artemether (4 mg/kg for 3 days
or 2 mg/kg for 7 days) alone or with oral doxycycline,
tetracycline or mefloquine (alone or combined with
SP) with or without primaquine. Eighteen patients
received oral dihydroartemisinin (4 mg/kg) in
replacement for one artesunate daily dose [26].
Supportive treatment was in accordance with guide-
lines [17,27]. Facilities for urinary catheter and naso-
gastric tube placement, blood transfusion and lumbar
puncture were available at Sangklaburi Hospital. In
addition, mechanical ventilation, peritoneal dialysis
and central venous access were available at Kanchanaburi
and Mae Sot.
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Six main models have been used to define severe malaria
in adults, those published by WHO and the AQ, MSA
and CAM scores [16-23] (Additional file 1). The accur-
acy of the APACHE II score [28] could not be assessed
as not all necessary laboratory variables were measured,
and the definition of WHO 1986 was not evaluated [16].
Data were not collected specifically for this analysis and
in order to examine the sensitivity and specificity of
WHO 1990 and 2000 definitions [17,18], minor adapta-
tions were made to allow assessment (Additional file 1,
Tables 1 and 2). Where the WHO 2000 definition [18]
does not include quantitative cut offs, the WHO 1990
[17] cut offs have been used. As blood pH, and hence
base deficit, data were not available, calculation of the
CAM score was not possible and so the modified CAM
scores, BCAM and RCAM were evaluated, using serum
bicarbonate and respiratory rate, respectively, as surro-
gates of acidosis (Tables 1 and 2).
Statistical analyses were performed using Stata (v11.0;
Stata Corporation, USA). All univariate comparisons be-
tween survivors and patients who died were performed
using logistic regression and adjusted for study site. Ten
sets of clinical and laboratory assay variables (Tables 1
and 2) were used to construct diagnostic rules to pre-
dict death. Logistic regression analysis with a stepwise
forward variable selection procedure was employed to
find independent predictors of death at P < 0.055, and
P ≥ 0.055 for entry and removal, respectively. Fractional
polynomials [29] were used to test for non-linear rela-
tionships between outcome variable and continuous co-
variates. All models were adjusted for artemisinin-based
combination therapy (ACT) and study site. The identi-
fied model was rerun on the maximum available sample
size and each of the variables not in the model were
tested for inclusion using the Wald test. The predictive
utility of each final model was assessed by receiver oper-
ating characteristic (ROC) curve analysis.
Malaria prognostic index
Variables selected into any final logistic regression
model, based on published criteria (see above), were
used to define the malaria prognostic index (MPI).
Since for all logistic models (above), inclusion of study
site as an independent variable did not improve the
model nor change the co-efficients for other covariates
significantly, it was not included in the development of
the MPI. Each variable was categorized into four
groups using rounded quartiles or commonly used cut
offs (as for GCS). Univariate logistic models (with sets
of corresponding binary variables) were fitted and cat-
egories with similar (P > 0.05) odds ratios (OR) were
grouped together. Co-efficients of the final multivariate
model were rounded to the nearest integer and used tocalculate for each patient a linear combination of vari-
ables (i. e, sum of variables multiplied by the rounded
co-efficients) – the MPI. The MPI was calculated for
each patient and the ROC analysis used to evaluate its
prognostic utility.
The predictive value of the MPI was further evaluated
using cross validation [30] on a subset of data with no
missing values for variables chosen to define MPI. Each
observation in this subset was sequentially removed, lo-
gistic regression with stepwise variable selection was
performed on the remaining n-1 observations using all
categorized variables, and the final model was used to
calculate sensitivity, specificity on n-1 observations and
classification results for the one excluded observation.
Co-efficients were rounded to integers and cut offs for
the linear predictor between two and six were used. For
each cut off, classification results for observations ex-
cluded from the subsequent models were used to calcu-
late jacknife estimates of sensitivity and specificity.
Results
Clinical presentation and outcome
Of 988 hospitalized patients enrolled (Tables 3, 4, 5, 6, 7
and 8), two thirds were men and ages ranged from 15 to
74 years. The percentages with severe malaria, as defined
by the WHO 1990, WHO 2000, adapted AQ, BCAM,
RCAM and MSA scores [17,18,20-22], were widely spread
at 61.2, 78.1, 41.7, 24.8, 22.7 and 5.6%, respectively (see
Additional files 2, 3, and 4). The overall mortality was 7.8%
(77/988). Using the WHO 1990, 2000 and adapted AQ def-
initions of severe malaria [17-20], the mortalities were
12.4%, 10% and 18.7%, in these groups, respectively.
Mortality did not significantly differ between the three
sites (9% in Kanchanaburi, 3% in Sangklaburi and 8% in
Mae Sot; P = 0.20). Artemisinin derivatives were given
to 7% of patients in Kanchanaburi, 77% in Sangklaburi
and 83% in Mae Sot (P < 0.001), reflecting temporal
changes in treatment policy and study protocols. Pa-
tients in Kanchanaburi had received prior malarial treat-
ment more frequently than at other sites and women
there were more often pregnant. Patients in Mae Sot
presented with lower coma scores (69% with coma score
of 15 compared to >80% at the other sites and 20% with
coma score ≤11 compared to 9-10% in the other sites),
higher parasitaemia, higher proportions of trophozoites
on admission film and a greater likelihood of a palpable
liver or spleen (Tables 3, 4, 5, and 6). However, other key
variables such as haematocrit, bicarbonate and lactate
were similar across all sites.
Forty-one admission variables were significantly associ-
ated (P < 0.05) with death on bivariate analysis (Tables 7
and 8). Variables previously associated with mortality that
were not significantly associated with death in our cohort
were patient age, the number of days of illness before
Table 4 Admission clinical examination details for the three study sites
Variable All patients Kanchanaburi Sangklaburi Mae Sot
N Number (%) N N N
Dehydration 781 428/353 (55) 424 182/242 (43) 41 13/28 (32) 316 233/83 (74)
Anaemia 932 274/658 (29) 529 161/368 (30) 68 10/58 (15) 335 103/232 (31)
Jaundice 969 226/743 (23) 561 137/424 (24) 72 9/63 (13) 336 80/256 (24)
Temperature °C a 963 38.5 (38.4-38.6) 552 38.4 (38.3-38.5) 74 38.5 (38.3-38.8) 337 38.7 (38.5-38.8)
Pulse/min a 927 101.0 (99.9-102.2) 519 97.4 (95.9-98.9) 73 103.1 (99.2-106.9) 335 106.2 (104.6-108.0)
BP systolic mmHg a 924 108.3 (107.3- 109.3) 515 107.5 (106.2-108.9) 71 105.7 (102.2-109.3) 338 110.1 (108.3-111.8)
BP diastolic mmHg a 918 65.5 (64.7-66.3) 513 64.3 (63.3-65.4) 71 68.8 (66.6-71.0) 334 66.7 (65.3-68.0)
Respiratory rate/min b 909 24.3 (23.8-24.7) 508 22.8 (22.2-23.3) 70 28.1 (26.6-29.8) 331 25.9 (25.2-26.6)
Abdominal tenderness 801 124/677 (15) 413 61/352 (15) 73 8/65 (11) 315 55/260 (17)
Liver palpable 870 338/532 (39) 500 183/317 (37) 68 7/61 (10) 302 148/154 (49)
Spleen palpable 885 190/695 (22) 506 94/412 (19) 71 0/71 (0) 308 96/212 (31)
Cranial nerve abnormalities 515 35/480 (7) 230 23/207 (10) 15 2/13 (13) 270 10/260 (4)
GCS Total 944 15 (3–15) 529 15 (3–15) 73 15 (3–15) 342 15 (3–15)
GCS Eyes 941 4 (1–4) 526 4 (1–4) 73 4 (1–4) 342 4 (1–4)
GCS Verbal 939 5 (1–5) 526 5 (1–5) 73 5 (1–5) 342 5 (1–5)
GCS Motor 941 6 (1–6) 526 6 (1–6) 73 6 (1–6) 342 6 (1–6)
Fundal haemorrhages 443 11/432 (3) 202 6/196 (3) 10 1/9 (10) 231 4/227 (2)
Number with/without or median (range) except a mean (95% CI) and b geometric mean (95% CI).
Table 3 Admission clinical history details for the three study sites
Variable All patients Kanchanaburi Sangklaburi Mae Sot
N Number (%) N N N
No. male 982 654 (67) 569 371 (65) 74 42 (57) 339 241 (71)
Age/years 979 27 (15–74) 564 26 (15–72) 73 25 (15–57) 342 28 (15–74)
Body weight/kg 929 51 (26–165) 544 51 (32–80) 70 50 (26–89) 315 51 (32–165)
Height/cm 441 160 (96–180) 199 160 (96–78) 2 154 (145–163) 240 160 (143–180)
BMI kg/ma 440 33.5 (32.8-34.2) 198 33.0 (32.3-33.8) 2 42.1 240 33.8 (32.7-34.8)
Prior malaria 780 445/335 (57) 464 256/208 (55) 52 26/26 (100) 264 163/101 (62)
Prior malarial drug 988 268/720 (27) 571 233/338 (41) 74 6/68 (8) 343 29/314 (9)
No. days ill 956 4 (1–31) 557 4 (1–31) 68 3 (1–30) 331 3 (1–21)
Females pregnant 328 76/252 (23) 198 70/128 (35) 32 5/27 (16) 98 1/97 (1)
Headache 921 843/78 (92) 520 484/36 (93) 72 66/6 (92) 329 293/36 (89)
Rigors 875 454/421 (52) 491 309/182 (63) 60 15/45 (25) 324 130/194 (40)
Vomiting 906 5 17/389 (57) 511 296/215 (58) 69 37/32 (54) 326 184/142 (56)
Diarrhoea 850 160/690 (19) 461 90/371 (24) 65 8/57 (12) 324 62/262 (19)
Abdominal pain 867 223/644 (26) 478 129/349 (27) 65 7/58 (11) 324 87/237 (27)
Cough 851 143/708 (17) 470 99/371 (21) 55 6/49 (11) 326 38/288 (12)
Seizures 836 28/808 (3) 456 9/447 (2) 60 1/59 (2) 320 18/302 (6)
Number with/without symptom or sign or median (range) except a mean (95% CI) and b geometric mean (95% CI). Percentages shown in brackets. Location of
hospitals included: Kanchanaburi (14.06 0 N, 99.50 0E), Sangklaburi 15.16 0 N 98.56 0E), Mae Sot (16.71 0 N 98.57 0E).
Newton et al. Malaria Journal 2013, 12:229 Page 5 of 14
http://www.malariajournal.com/content/12/1/229
Table 5 Admission haematology laboratory details for the three study sites
Variable All patients Kanchanaburi Sangklaburi Mae Sot
N Number (%) N N N
Parasitaemia /μLb,c 953 72,694 (64.402-82,054) 540 53,766 (45,785-63,138) 74 71,793 (51,736-99,625) 339 117,827 (95,989-144,633)
Rings % 874 97 (1–100) 486 97 (6–100) 66 98 (42–100) 322 95 (1–100)
Trophozoites % 874 3 (0–99) 486 2.5 (0–94) 66 2.0 (0–58) 323 4.0 (0–99)
Schizonts % 876 0 (0–25) 486 0 (0–12) 67 0 (0–6) 320 0 (0–25)
Pigmented stages > 104/L 868 274/594 (32) 482 121/361 (25) 66 13/53 (20) 322 140/180 (43)
Trophozoites and schizonts% 874 4 (0–99) 486 3 (0–94) 66 2 (0–58) 321 5 (0–99)
Modal Stage % 833 55 (19–99) 446 56 (19–99) 66 70 (30–96) 339 53 (23–97)
Haematocrit % 962 37 (6–56) 549 37 (8–56) 74 38 (22–50) 285 38 (6–54)
Haemoglobin g/dL a 761 11.3 (11.1-11.5) 476 10.9 (10.7-11.1) 0 - 314 12.0 (11.6-12.3)
White cells x 109/L 889 6.8 (1.5-67.0) 519 6.6 (1.8-67) 56 5.7 (1.5-25) 292 7.1 (1.9-54)
Neutrophils % 863 75 (12–97) 507 73 (31–97) 64 74 (12–96) 281 77 (41-96)
Platelets x109/L 527 74 (0.5-404) 246 105 (16–384) 0 - 329 45 (1–404)
c number of asexual parasites/1000 erythrocytes on thin film x haematocrit% × 125.6 or number of asexual parasites/200 white cells on thick film assuming white
cell count 8 × 109/L.
Newton et al. Malaria Journal 2013, 12:229 Page 6 of 14
http://www.malariajournal.com/content/12/1/229admission, and plasma glucose. Although there was no ap-
parent overall relationship between mortality and age, mor-
tality was higher with increasing age for those treated with
quinine (OR (95% CI) 1.029 (1.006-1.051) P = 0.012), but
not for those treated with artemisinins (OR 0.953 (0.904-
1.005) P = 0.078).Table 6 Admission biochemistry laboratory variables for the
Variable All patients Kanchan
N value N v
Sodium mmol/L, d S 764 135.4 (93.8-155.0) 419 1
Potassium mmol/L, e S 761 3.81 (1.2-7.51) 417 3
Creatinine μmol/L f S 880 105.6 (35.2-1056) 475 1
Urea mmol/L g S 892 19.5 (3.5-226.5) 484 6
Urea mmol/L:creatinine μmol/L ratio 879 0.070 (0.005-0.256) 474 0
Total bilirubin μmol/L b,h, S 859 28.9 (26.8 - 31.0) 456 2
Direct bilirubin μmol/L I, S 847 8.5 (0.3-488.6) 451 8
Alkaline phosphatase IU/L b,j, S 844 43.2 (41.1-45.3) 442 3
AST IU/L k, S 858 41 (0.4-1795) 455 3
ALT IU/L b,l, S 856 20.7 (19. 5–22.0) 456 1
Albumin g/L a,m, S 862 33.7 (33.2-34.2) 459 3
Calcium (uncorrected) mmol/L a,n, S 397 2.06 (1.47-2.56) 0 -
Phosphate mmol/Lb,o,S 291 0.82 (0.32-2.65) 0 -
Bicarbonate mmol/L a,p, S 687 20.5 (20.2-20.8) 348 2
Chloride mmol/L a,q, S 752 102.2 (101.7-102.7) 407 1
Glucose mmol/L r, P 846 6.4 (0.7-37. 5) 447 6
Lactate mmol/L s, P 805 2.7 (0.3-27.6) 414 2
Number with/without or median (range) except a mean (95% CI) and b geometric m
d normal range 135–145 mmol/L; e normal range 3.5-5.5 mmol/L; f normal range 70
I normal range 1.7-5.1 mmol/L; j normal range 30–300 IU/L; k normal range 5–35
2.2-2.6 mmol/L; o normal range 1.0-1.4 mmol/L; p normal range 21–28 mmol/L; q norPrognostic value of parasite staging
Staging of parasite development on peripheral blood
smears provides prognostic information additional to the
parasite count itself; the median percentage of ring stages
amongst those who survived was 98% and amongst those
who died 48% (P = 0.0001). The percentage of the modalthree study sites
aburi Sangklaburi Mae Sot
alue N value N value
37.8 (94–155) 16 136.5 (130–141) 328 133 (111–146)
.8 (1.2-7.5) 16 3.70 (3.3-4.3) 331 3.9 (1.8-7.1)
14 (35–1056) 74 97 (66–202) 334 106 (39–836)
.5 (1.5-56) 74 6.7 (2.5-18.7) 334 7.7 (1.3-81)
.060 (0.005-0.244) 74 0.067 (0.022-0.014) 331 0.078 (0.021-0.026)
3.6 (21.1-26.4) 73 29.4 (24.5-35.2) 330 38.0 (34.6-41.8)
.5 (0.3-487) 72 6.1 (1.5-152) 324 9.9 (1.0-389)
1.5 (29.8-33.3) 73 34.9 (31.9-38.2) 329 69.2 (64.2-74.6)
3 (5–210) 73 43 (0.4-183) 330 52 (10–1795)
9.2 (17.6-21.1) 73 24.5 (21.3-28.2) 327 22.2 (20.4-24.1)
1.9 (31.2-32.7) 73 38.6 (37.0-40.1) 330 35.0 (34.3-35.7)
73 2.12 (2.09-2.15) 324 2.05 (2.04-2.07)
73 1.19 (0.32-1.87) 218 0.81 (0.32-2.65)
1.0 (20.5-21.4) 16 20.4 (18.9-22.0) 323 20.0 (19.4-20.5)
03.7 (103.0-104.3) 16 103.3 (101.2-105.3) 329 100.2 (99.6-100.8)
.2 (1.5-38) 70 6.2 (3.5-25) 329 7.3 (0.7-31.1)
.7 (0.4-28) 74 2.2 (0.9-16) 317 2.8 (0.3-22)
ean (95% CI).
–150 μmol/L; g normal range 2.5-6.7 mmol/L; h normal range 5.1-17 μmol/L;
IU/L; l normal range 5–35 IU/L; m normal range 35–50 g/L; n normal range
mal range 95–105 mmol/L; r normal range 3.5-5.5 mmol/L; s normal <4 mmol/L.
Table 7 Admission clinical variables for those who died and survived
Variable All patients Survived Died P
N % N % N %
No. male 982 654 67 906 598 66 76 56 74 0.197
Age/years 979 27 (15–74) - 905 27 (15–74) - 74 26 (15–67) - 0.410
Body weight/kg 929 51 (26–165) - 861 51 (26–165) - 68 50 (40–75) - 0.715
Prior malaria 780 445/335 57 748 438/310 59 32 7/25 22 <0.001
Prior malarial drug 988 268/720 27 911 242/669 27 77 26/51 34 0.310
No. days ill 956 4 (1–31) - 886 3 (1–31) - 70 4 (1–20) - 0.836
No. females pregnant 328 76/252 23 308 75/233 24 20 1/19 5 0.049
Headache 921 843/78 92 866 794/72 94 55 49/6 89 0.511
Rigors 875 454/421 52 821 428/393 52 54 26/28 48 0.522
Vomiting 906 517/389 57 855 484/371 56 51 33/18 65 0.268
Diarrheoa 850 160/690 19 805 152/653 19 45 8/37 18 0.805
Abdominal pain 867 223/644 26 823 215/608 26 44 8/36 18 0.200
Cough 851 143/708 17 806 136/670 17 45 7/38 16 0.897
Seizures 836 28/808 3 786 18/768 2 50 10/40 20 <0.001
Dehydration 781 428/353 55 734 395/339 54 47 33/14 70 0.063
Anaemia 932 274/658 29 862 236/626 27 70 38/32 54 <0.001
Jaundice 969 226/743 23 892 175/717 20 77 51/26 66 <0.001
Temperature o C a 963 38.5 (38.4 - 38.6) - 892 38.6 (38.5-38.6) - 71 38.0 (37.7-38.3) - <0.001
Pulse/min a 927 101.0 (99.9-102.2) - 856 100.1 (99.0-101.2) - 71 113.3 (108.6–117.9) - <0.001
BP systolic mmHg a 924 108.3 (107.3-109.3) - 851 107.9 (106.9-108.9) - 73 113.5 (108.4– 118.5) - 0.004
BP diastolic mmHg a 918 65.5 (64.7-66.3) - 846 65.4 (64.6-66.2) - 72 66.8 (63.6-70.0) - 0.247
Respiratory rate/min b 909 24.3 (23.8-24.7) - 837 23.9 (23.5-24.3) - 71 29.2 (26.9 - 31.6) - <0.001
Abdominal tenderness 801 124/677 15 743 116/627 16 58 8/50 14 0.689
Liver palpable 870 338/532 39 800 299/501 38 70 39/31 56 0.005
Spleen palpable 885 190/695 22 818 172/646 21 67 18/49 27 0.308
Cranial nerve abnormalities 515 35/480 7 467 20/447 4 48 15/33 31 <0.001
GCS Total 944 15 (3–15) - 882 15 (3–15) - 62 9 (3–15) - <0.001
GCS Eyes 941 4 (1–4) - 881 4 (1–4) - 60 4 (1–4) - <0.001
GCS Verbal 939 5 (1–5) - 881 5 (1–5) - 58 1 (1–5) - <0.001
GCS Motor 941 6 (1–6) - 881 6 (1–6) - 60 5 (1–6) - <0.001
Fundal haemorrhages 443 11/432 3 389 4/385 1 54 7/47 13 <0.001
Number with/without or median (range) except a mean (95% CI) and b geometric mean (95% CI). Footnotes as for Table 3.
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who died than in those who survived (P = 0.0002),
suggesting that lower circulating parasite stage syn-
chronicity was associated with death. Using the cut
offs of Silamut and White of pigmented stages >104/μL
or a parasitaemia of >5 x 105/μL [7], the sensitivity and
specificity for predicting death were 84% and 67%,
respectively.
Therapeutic responses
The median (range) coma recovery time and time to death
were 24 (1–188) h (N = 46) and 44 (2–641) h (N = 76)respectively (Table 9). Artemisinin derivative-based therapy
was given to 378/958 (39%) of patients starting in 1993,
and artesunate or artemether was given to 317/759
(42%) of those administered a parenteral anti-malarial.
A significantly higher proportion of patients had severe
disease (as defined using adapted AQ criteria) in the
artemisinin derivative group (46%) than the non-
artemisinin group (40%) (P < 0.001). However, the mor-
tality in those given parenteral artesunate or artemether
(16/317, 5%) was lower than those given parenteral
quinine (59/442, 13%) (P < 0.001). No patient without
severe disease who received oral anti-malarial treatment
Table 8 Admission laboratory variables for those who died and survived
Variable All patients Survived Died P
N value N value N value
Admission parasitaemia μLb,c 953 72,694 (64,402–82,054) 883 68,850 (60,837-77,917) 70 144,012 (86,460-239,876) 0.002
Rings% 874 97 (1–100) 811 98 (1–100) 63 48 (1–100) <0.001
Trophozoites% 874 3 (0–99) 811 2 (0–99) 63 52 (0–99) <0.001
Schizonts% 876 0 (0–25) 813 0 (0–6) 63 0 (0–25) <0.001
Pigmented stages > 104/L 868 274/594 (32%) 805 227/578 (28%) 63 47/16 (75%) <0.001
Trophozoites and schizonts % 874 4 (0–99) 811 2 (0–99) 63 52 (0–99) <0.001
Modal Stage % 833 55 (19–99) 779 56 (23–99) 54 47 (19–94) 0.001
Haematocrit % 962 37 (6–56) 888 37 (6–56) 74 33 (12–50) <0.001
Haemoglobin g/dL a 761 11.3 (11.1- 11.5) 704 11.4 (11.2- 11.6) 57 10.1 (9.5 -10.8) <0.001
White cells x 109/L 889 6.8 (1.5-67.0) 818 6.6 (1.5 - 67) 71 11.2 (2.4 - 63) <0.001
Neutrophils% 863 75 (12–97) 796 75 (12–97) 67 72 (36–95) 0.101
Platelets 109/L 527 74 (0.5-404) 491 75 (0.5 - 404) 36 50 (4–188) 0.001
Sodium mmol/L, d, S 764 135.4 (93.8-155.0) 698 135.3 (100.4-155.0) 66 136.7 (93.8–153.0) 0.618
Potassium mmol/L, e, S 761 3.81 (1.2-7.51) 696 3.80 (2.0 –7.51) 65 4.50 (1.2-7.1) <0.001
Creatinine μmol/L f, S 880 105.6 (35.2 - 1056) 810 105.6 (35.2 - 1056) 70 240 (46.6 - 880) <0.001
Urea mmol/L g, S 892 19.5 (3.5-226.5) 821 18.7 (3.5-138) 71 58.2 (10.7 - 227) <0.001
Urea mmol/L:creatinine μmol/L ratio 879 0.070 (0.005-0.256) 809 0.065 (0.005-0.257) 70 0.078 (0.030-0.260) <0.001
Total bilirubin μmol/L b,h 859 28.9 (26.8 - 31.0) 797 26.4 (24.6-28.4) 62 90.6 (69.6-118.1) <0.001
Direct bilirubin μmol/L i 847 8.5 (0.3-488.6) 787 8.3 (0.3 - 489) 60 40.3 (1.4 - 389) <0.001
Alkaline phosphatase IU/L b,j 844 43.2 (41.1-45.3) 781 42.1 (40.0-44.2) 63 60.7 (50.5-72.8) <0.001
AST IU/L k 858 41.0 (0.4-1795) 796 40 (0.4 - 1795) 62 95 (22–1200) 0.001
ALT IU/L b,l 856 20.7 (19. 5–22.0) 794 19.7 (18.5-20.9) 62 41.3 (33.6-50.8) <0.001
Albumin g/L a,m 862 33.7 (33.2-34.2) 798 33.9 (33.4-34.4) 64 30.6 (28.5-32.7) 0.001
Calcium (uncorrected) mmol/L a,n 397 2.06 (1.47-2.56) 369 2.06 (1.52-2.56) 28 2.06 (1.47-2.40) 0.385
Phosphate mmol/L b,o 291 0.82 (0.32-2.65) 272 0.81 (0.32-2.10) 19 1.23 (0.48-2.65) <0.001
Serum bicarbonate mmol/L a,p 687 20.5 (20.2-20.8) 629 21.0 (20.7-21.3) 58 14.7 (13.1-16.3) <0.001
Serum chloride mmol/L a,q 752 102.2 (101.7-102.7) 688 102.3 (101.9-102.7) 64 100.6 (98.0-103.2) 0.023
Plasma glucose mmol/L r 846 6.4 (0.7-37. 5) 778 6.4 (0.7 - 38) 68 6.8 (2.2-18.5) 0.139
Plasma lactate mmol/L s 805 2.7 (0.3-27.6) 741 2.5 (0.3 - 22) 64 8.5 (1.9 - 28) <0.001
Number with/without or median (range) except a mean (95% CI) and b geometric mean (95% CI). Footnotes as for Tables 3, 5 and 6.
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such as oliguria, seizures or pulmonary oedema and the
use of ventilation, lumbar puncture, transfusion and
inotropes, were all associated with death (Table 10).
Mortality decreased with time, from 9% in 1986–1992
to 7% in 1993–1998 and 6% in 1999–2002 (OR = 0.943
(0.896-0.994), P = 0.030). There was increasing use of
artemisinin derivatives over the same periods (0%, 72%
and 93% of patients, respectively) and the correspond-
ing percentages of parenteral treatments that were with
intravenous/intramuscular artemisinin derivative were
0%, 67% and 93%, respectively. After adjusting for treat-
ment type and study site, there was no trend in mortal-
ity over time (OR = 0.961 (0.847-1.091), P = 0.538).Relationships between clinical syndromes
Of 111 patients with cerebral malaria (GCS < 11), 97
had evaluable data. Of these, 68 (70%) had plasma lac-
tate >4 mmol/L and/or serum bicarbonate <15 mmol/L
and/ or serum creatinine >264 μmol/L, and 36 (53%)
of these died compared with three (10%) among 29
cerebral malaria patients without these abnormalities
(P = 0.001). Among cerebral malaria patients, mortality
did not significantly differ between those with and with-
out jaundice (total serum bilirubin >50 μmol/L): 42%
(23/55) versus 34% (15/44) (P = 0.547). Mortality was
higher in patients with renal impairment; 82% (18/22) in
those with a serum creatinine >264 μmol/L compared
with 28% (23/83) in those with lower levels (P < 0.001).
Table 9 Anti-malarial drug treatment and outcome
Variable All Alive Died
+/− % +/− % +/− %
Non-artemisinin/artemisinin derivative therapy 580/378 60.5 521/362 59.0 59/16 78.7
Parenteral quinine/artemisinin derivative. Patients given both parenteral
quinine and artemisinin derivatives excluded
430/276 60.9 371/261 58.7 59/15 79.7
Oral quinine/artemisinin derivative and no parenteral anti-malarial 93/60 60.8 93/60 60.8 0/0 -
Number given/not given antibiotic a 124/818 13.2 94/778 10.8 30/40 42.9
No. given/not given inotrope 65/872 6.9 13/856 1.5 52/16 76.5
No. given/not given anti-epileptic drug 97/843 10.3 59/812 6.8 38/31 55.1
No. given/not given nasogastric tube 65/859 7.0 36/828 4.2 29/31 48.3
No. given/not given urinary catheter 207/728 22.1 142/725 16.4 65/3 95.6
No. given/not given blood transfusion 160/828 16.2 132/779 14.5 28/49 36.4
No. given/not given dialysis 31/898 3.3 7/854 0.8 24/44 77.4
No. given/not given ventilation 85/845 9.1 25/839 2.9 60/6 90.9
No. given/not given central venous access line 99/840 10.5 45/825 5.2 54/15 78.3
No. given/not given lumbar puncture 90/849 9.6 56/813 6.4 34/36 48.6
No. developing/not developing pulmonary oedema 14/958 1.4 7/888 0.8 7/70 9.1
No. developing/not developing oliguria 94/843 10.0 43/826 5.0 51/17 75.0
No. developing/not developing seizures 39/909 4.1 20/852 2.3 19/57 25.0
No. of nights in hospitalb 4 (1–34) - 4 (1–34) - 2 (1–27) -
Coma Recovery Time/hb 24 (1–188) - - - - -
Time to death/hb - - - - 44 (2–641) -
a excluding doxycycline and tetracycline given for malaria. b Median (range). All comparisons between alive and dead were statistically significant (P < 0.001,
adjusted for study site).
Newton et al. Malaria Journal 2013, 12:229 Page 9 of 14
http://www.malariajournal.com/content/12/1/229Multiple logistic regression analysis of variables
associated with death
All final models were adjusted for treatment with ACT
and study site. No interactions between covariates and
treatment were significant in any of the models and
study site was not significant (P > 0.05). Tables 10 and
11 list variables included in each of the eight final
models, all having a maximum of eight variables, consist-
ent with recommendations [31].
Considering the WHO- and AQ-based models, the
WHO 1990, WHO 2000, Adapted AQ and Adapted AQ +
Pigmented stages, variable sets gave the best predictive
power and the areas under the ROC curves (AUROCCs)
were not significantly different (Tables 10 and 11,
Additional files 2, 3, and 4). Models derived from bedside
or bedside + simple laboratory covariates had significantly
smaller AUROCCs, when compared to the Adapted AQ
model using the common data set (P = 0.008 and 0.016,
respectively). Several variables appeared in all four ‘best’
models and had similar effects across models, such as
GCS (OR 0.67-0.73 for increase by one point), serum bi-
carbonate (OR 0.84-0.86 for increase of 1 mmol/L), plasma
lactate (OR 1.20-1.34 for increase of 1 mmol/L), parasit-
aemia (OR 1.90-4.06 for ten-fold increase) and serum cre-
atinine (OR 1.005-1.006 for increase of 1 μmol/L).The BCAM and RCAM scores could be calculated for
662 and 873 patients, respectively, and mortality rose
with increasing score for both (Table 12). Of 498 pa-
tients with a low BCAM (<2) score, three (0.6%) died
(PPV (95%CI) for survival 99.4 (98.2–99.8)%), and of
the 675 patients with low RCAM (<2) score, 11
(1.6%) died (PPV for survival 98.4 (97.1-99.1)%). The
BCAM score AUROCC as a predictor for mortality was
0.907 (0.861-0.953) and that for the RCAM score
0.86 (0.81-0.91)(P = 0.050). A score <2 was an optimal
cut-off value in this data set for both BCAM and RCAM,
with sensitivity and specificity of 93.8% and 80.6% for
BCAM and 81% and 81% for RCAM.
For the MSA score [22] (Additional file 1) using admis-
sion variables plus the presence or absence of mechanical
ventilation during admission where such ventilation was
available (all sites except Sangklaburi) for 635 patients,
516 (81.3%) had an MSA score of 0. Mortality was 2/539
(0.4%) for MSA 0–2, 10/45 (22.2%) for MSA 3–4, 5/12
(41.7%) for MSA 5–6 and 24/39 (61.5%) for MSA ≥7.
If ≥5 is taken as the cut off, the PPV for survival was
97.9 (96.4-98.8)%. Among patients who had MSA and
BCAM scores calculated (n = 527) the AUROCC for the
MSA score in predicting death was 0.97 (0.95-0.98), which
was significantly better than that for the BCAM score 0.90
Table 10 Summary of multiple logistic regression models for outcome for Bedside and WHO models
Covariate OR 95% CI P value AUROCC 95% CI
Bedside 0.93 (0.90-0.96)
Anaemia 2.510 1.173 5.373 0.018
Jaundice 3.235 1.534 6.823 0.002
Temperature 0C 0.673 0.490 0.926 0.015
Pulse/min 1.031 1.007 1.056 0.010
Respiratory rate/min 1.061 1.010 1.115 0.018
GCS 0.717 0.654 0.785 <0.001
Treatment with ACT 0.387 0.134 1.118 0.080
Bedside + Simple Lab 0.96 (0.93 -0.98)
Temperature 0C 0.579 0.405 0.829 0.003
Respiratory rate/min 1.081 1.027 1.139 0.003
Log10 parasitaemia 8.606 3.525 21.011 <0.001
GCS 0.663 0.589 0.745 <0.001
% Trophozoites and schizonts 1.029 1.014 1.045 <0.001
Treatment with ACT 0.253 0.078 0.825 0.023
WHO (1990) 0.95 (0.90-1.00)
GCS 0.673 0.590 0.767 <0.001
Serum creatinine μmol/L 1.005 1.001 1.009 0.007
Serum bicarbonate mmol/L 0.844 0.763 0.934 0.001
Serum total bilirubin μmol/L 1.006 1.001 1.010 0.011
Log10 parasitaemia 1.902 1.060 3.410 0.031
Treatment with ACT 0.838 0.224 3.142 0.794
WHO (2000) and Adapted AQ a 0.97 (0.96-0.99)
GCS 0.673 0.582 0.778 <0.001
Serum bicarbonate mmol/L 0.856 0.747 0.980 0.024
Serum lactate mmol/L 1.197 1.052 1.362 0.006
Log10 parasitaemia 2.460 1.168 5.182 0.018
Serum creatinine μmol/L 1.006 1.002 1.010 0.003
Treatment with ACT 1.000 0.220 4.555 1.000
All estimates are adjusted for treatment with ACT and study site. a the same variables were identified from the WHO (2000) and Adapted AQ models.
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presented here appeared to be <3 rather than <5 as
reported [22]; with a cut off of <3 the PPV was 99.6
(98.7-100.0)%, sensitivity 95.1% and specificity 90.4%.
Considering all ten models, those based on the MSA
score and the Adapted AQ with pigmented parasites had
the best predictive power, but AUROCCs for models
based on WHO criteria were not significantly lower.
Simple rules for classification of severity as a MPI (Table 13,
Figure 1), gave sensitivity of 100% and specificity of
82% with co-efficient of 3 rounded to the nearest in-
teger, and sensitivity of 93% and specificity of 92% for a
cut off of 4. When compared to the best performing
models, based on MSA and Adaptive AQ + Pigmented
stages, MPI showed equally good predictive power:AUROCC = 0.96 (0.95-0.98) for MPI rounded to the
nearest integer, and 0.97 (0.96-0.99) for MPI rounded
to the nearest 0.5 compared to 0.98 (0.96-0.99) for
MSA and 0.97 (0.94-0.99) for AQ dataset, based on
450 patients who could be evaluated in all four models.
In cross-validation, in all runs, the best sensitivity and
specificity were obtained for cut offs between 3 and 4
(Figure 2). For a cut off of 3, the jacknife sensitivity
and specificity were 97.1% and 87.1%; for a cut off of
3.5 they were 97.1% and 87.1%; and for a cut off of 4
they were 74% and 94%.
Discussion
The prognosis of severe falciparum malaria has improved
markedly since the introduction of parenteral artesunate
Table 11 Summary of multiple logistic regression models for outcome for Adapted AQ + pigmented stages, BCAM and
RCAM models
Covariate OR 95% CI P value AUROCC 95% CI
Adapted AQ + pigmented stages 0.97 (0.96-0.99)
GCS 0.728 0.641 0.828 <0.001
Plasma lactate mmol/L 1.341 1.190 1.510 <0.001
Serum creatinine μmol/L 1.006 1.003 1.009 <0.001
% Trophozoites & schizonts 1.026 1.009 1.043 0.003
Log10 parasitaemia 4.064 1.506 10.969 0.006
Treatment with ACT 0.438 0.103 1.869 0.265
BCAM 0.92 (0.87-0.97)
GCS/15 0.718 0.652 0.791 <0.001
Serum bicarbonate mmol/L 0.780 0.717 0.849 <0.001
Treatment with ACT 0.718 0.230 2.237 0.568
RCAM 0.88 (0.84-0.93)
GCS/15 0.680 0.627 0.736 <0.001
Respiratory rate/min 1.097 1.055 1.141 <0.001
Treatment with ACT 0.329 0.126 0.857 0.023
All estimates are adjusted for treatment with ACT and study site.
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arum malaria admitted to hospitals in western Thailand
spanned the transition from quinine to artemisinins, and
although the data were not from a randomized compari-
son, mortality was substantially lower in patients who re-
ceived artemisinin derivatives. Despite the effect of changes
in anti-malarial therapy, prognostic indices based on
WHO 2000 definitions, and other simpler indices based on
fewer variables, provided clinically useful predictions of
outcome in Asian adults with severe malaria.
Models using variable sets based on WHO 2000 and
Adapted AQ with pigmented stages gave the best predic-
tion of mortality, and were comparable to the results
based on the MSA score using a smaller sample. Very
similar results were also obtained with the MPI based on
the most commonly selected variables, GCS, plasma lac-
tate, parasitaemia, serum bilirubin and percentage of
pigmented parasites. This will need to be evaluated in
independent series of adults with falciparum malaria in
similar settings of unstable malaria transmission. This
score suffers from the disadvantage, unlike the RCAM
score, that determination of 4/5 variables (all except GCS)Table 12 Mortality among patients by BCAM and RCAM score
Score, Outcome 0 1 2
BCAM
Died/total (%) 1/124 (0.8) 2/374 (0.5) 12/79
RCAM
Died/total (%) 0/97 (0) 11/578 (1.9) 12/108requires skilled technicians and equipment/consumables
and quality assurance that are seldom available where se-
vere malaria is common.
There are at least four limitations of this analysis:
specifically, not all patients admitted to the study
hospitals were recruited, recruitment criteria varied,
there are missing values, and a variety of different
doctors reviewed the patients with consequent vari-
ability in the nature of both clinical assessment and
inpatient management. However, any such differences
are likely to result in false negative, rather than false
positive associations. The MSA score differs from the
others scores discussed, as it is not strictly an admis-
sion predictive prognostic score, including mechan-
ical ventilation during hospitalization. Some potential
prognostic factors such as haemoglobinuria and ab-
normal bleeding were too infrequent to allow reliable
conclusions to be drawn. Serum bilirubin and plasma
lactate were not measured in the South East Asian
Quinine Artesunate Malaria Trial (SEAQUAMAT)
and therefore the MPI could not be calculated for
this dataset [21].s
3 4 Total
(15.2) 16/60 (26.7) 17/25 (68.0) 48/662 (7.3)
(11.1) 25/74 (33.8) 11/16 (68.8) 59/873 (6.8)
Table 13 Prognostic index for severe malaria
N = 668 / n = 43 Co-efficient
MPI A MPI B
GCS <5 4.318 4 4.5
GCS 5-11 1.543 2 1.5
Parasitaemia >315,000/μL 1.238 1 1
Plasma lactate > 5 mmol/L 2.267 2 2.5
Serum bilirubin > 58 μmol/L1 1.191 1 1
Pigmented parasites >20% 1.673 2 1.5
Treatment with ACT −1.280 −1 −1.5
AUROCC 0.97 0.97 0.97
Cut off 2 3 3
Sensitivity 100% 100%
Specificity 82% 88%
Cut off 3 4 3.5
Sensitivity 93% 95%
Specificity 92% 91%
MPI A = co-efficients rounded to the nearest integer with cut offs of 3.
MPI B = co-efficients rounded to the nearest 0.5 with cut offs of 3.
1 if not available; creatinine >132 μmol/L can be used instead.
and cut off of 3 would give sensitivity and specificity of 98%.
and 82% for MPI A and 96% and 88% for MPI B.
2 which gives the highest specificity for 100% sensitivity.
3 which gives the “optimal” sensitivity and specificity.
Figure 2 Sensitivity (filled circle) and specificity (empty circle)
for different cut offs of malaria prognostic index in
cross validation.
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only included patients classified as having severe malaria
and was designed to determine which subset of patients
could safely be managed without ICU referral. This is
reflected in the relatively low mortality in the series de-
scribed here, as severe malaria was not necessarily a cri-
terion for recruitment. The broader patient population
included may well explain the inclusion of parasitaemia
as predictive of death in this series and not in that of
Hanson [23]. As this series includes many patientsFigure 1 Relationshipbetweenmalariaprognostic index andmortality.
Malaria prognostic indicesMPI A andMPI B are defined in Table 13.without severe disease, the specificity of variables in
predicting death may be higher than in series includ-
ing patients with pre-selected severe disease. However,
in busy clinical practice a tool that could define unse-
lected patients admitted to hospital as at risk of death
would be valuable.
The wide variation in mortality estimates in this dataset
among those with severe malaria (10-18%) and indeed the
wide range of estimates of severe disease (6–60%), depend-
ing on which definition is used, illustrates the importance
of definitions in comparisons between studies, in meta-
analyses, and in understanding the host and geographical
variability in the presentation and outcome of severe mal-
aria. Various terms, such as ‘uncomplicated’ and ‘mild’, are
used to refer to malaria that is not severe. Severe disease is
also equated with ‘complicated’ malaria. To avoid confu-
sion, terminology should be standardized with ‘severe’
malaria referring to malaria with clinical and/or labora-
tory features suggesting a clinically significant risk of
death (e.g. >5%) despite anti-malarial treatment, and ‘un-
complicated’ as those without such prognostic features
and that the terms ‘complicated’ and ‘mild’ are not used.
The present study suggests that, if laboratory tests are
available, the history of the illness and the physical
examination, apart from GCS and respiratory rate, are
relatively unimportant in assessing prognosis in a popula-
tion of malaria patients. Unlike in other series [13], in-
creased age was not associated with death, except for
those treated with quinine. However, as this series did
not include children and a smaller percentage (7.7%)
were >50 years old, the age range was narrower.
In this series, the mortality of cerebral malaria was
increased three-fold if concurrent acidosis and/or renal
failure were present and these factors are crucial in
predicting death. The ease of identifying patients with
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tions less of a focus and these data suggest that more re-
search on the pathophysiology and treatment of acidosis
and renal dysfunction would provide information that
would improve management and outcome [12,14,32].
The use of relatively inexpensive plasma lactate portable
meters may assist in the triage of patients in tropical hos-
pitals without access to biochemical analyzers, and inter-
ventions directed at acidosis and renal impairment might
reduce mortality. Although capital costs for veno-venous
haemofiltration are relatively high, and intensive care
support is required, running costs in comparison to peri-
toneal dialysis are low [33]. In areas of the Asiatic tropics
with good communications but low health expenditure,
regional centres for the management of severe malaria
through haemofiltration may assist in lowering mortality.
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